A Look at Becton, Dickinson's Upcoming Earnings Report
Becton, Dickinson (NYSE:BDX) is gearing up to announce its quarterly earnings on Monday, 2026-02-09. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Becton, Dickinson will report an earnings per share (EPS) of $2.82.
Anticipation surrounds Becton, Dickinson's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
Earnings History Snapshot
The company's EPS beat by $0.05 in the last quarter, leading to a 0.25% increase in the share price on the following day.
Here's a look at Becton, Dickinson's past performance and the resulting price change:
| Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| EPS Estimate | 3.91 | 3.41 | 3.28 | 2.99 |
| EPS Actual | 3.96 | 3.68 | 3.35 | 3.43 |
| Price Change % | 0.00 | 3.00 | 0.00 | -7.00 |
Stock Performance
Shares of Becton, Dickinson were trading at $206.51 as of February 04. Over the last 52-week period, shares are down 10.04%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.
Analysts' Perspectives on Becton, Dickinson
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Becton, Dickinson.
Becton, Dickinson has received a total of 5 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $209.4, the consensus suggests a potential 0.74% upside.
Comparing Ratings Among Industry Peers
The below comparison of the analyst ratings and average 1-year price targets of IDEXX Laboratories, Edwards Lifesciences and ResMed, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
- Analysts currently favor an Outperform trajectory for IDEXX Laboratories, with an average 1-year price target of $795.0, suggesting a potential 282.45% upside.
- Analysts currently favor an Buy trajectory for Edwards Lifesciences, with an average 1-year price target of $97.35, suggesting a potential 53.17% downside.
- Analysts currently favor an Neutral trajectory for ResMed, with an average 1-year price target of $286.29, suggesting a potential 37.73% upside.
Analysis Summary for Peers
Within the peer analysis summary, vital metrics for IDEXX Laboratories, Edwards Lifesciences and ResMed are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| Becton Dickinson | Neutral | 8.35% | $2.80B | 1.94% |
| IDEXX Laboratories | Outperform | -1.33% | $683.35M | 15.68% |
| Edwards Lifesciences | Buy | 14.67% | $1.21B | 2.81% |
| ResMed | Neutral | 10.98% | $878.72M | 6.31% |
Key Takeaway:
Becton, Dickinson ranks in the middle for revenue growth among its peers. It has the lowest gross profit and return on equity compared to others.
Unveiling the Story Behind Becton, Dickinson
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.
Understanding the Numbers: Becton, Dickinson's Finances
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Becton, Dickinson showcased positive performance, achieving a revenue growth rate of 8.35% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Becton, Dickinson's net margin is impressive, surpassing industry averages. With a net margin of 8.37%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.94%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Becton, Dickinson's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.89%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.76, Becton, Dickinson adopts a prudent financial strategy, indicating a balanced approach to debt management.
To track all earnings releases for Becton, Dickinson visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.